BMO Capital Keeps Their Buy Rating on Gilead Sciences (GILD)
BMO Capital analyst Evan Seigerman reiterated a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $120.00. The company’s shares closed today at $108.00. Confident Investing Starts Here: Seigerman covers the Healthcare …